Product Information
LEVOXYL 137 MCG TABLET is a brand product labeled by Pfizer Inc., priced at $1.1503 per EA under NDC 60793085701. Its NADAC has been published 611 times since Apr 23, 2014.
FDA first approved this application on May 25, 2001. Its Orange Book therapeutic-equivalence code is AB1,AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
137 ug/1
Manufacturer
Pfizer Inc.NDC
60793085701
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOTHYROXINE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021301FDA Approved
5/25/2001
TE Code
AB1,AB3
On Market Since
5/25/2001
Pharmacological Classes
Price Statistics
The NADAC for LEVOXYL 137 MCG TABLET has been published 611 times since Apr 23, 2014, and over the history we have for it it has risen 129.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1503 per EA |
|---|---|
| All-time high | $1.1520 (Jun 10, 2026) |
| All-time low | $0.5003 (Apr 23, 2014) |
| 52-week high | $1.1520 |
| 52-week low | $1.0951 |
| Median price | $1.0297 |
| Average price | $0.9450 |
| Largest weekly change | +9.4% (Jul 4, 2018) |
| Weeks tracked | 611 |
| Tracking since | Apr 23, 2014 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 94% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levothyroxine sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
l-Thyroxine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOXYL 137 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOXYL 137 MCG TABLET, manufactured by Pfizer Inc., is $1.1503 per EA (NDC 60793085701), effective Sep 30, 2026.
How has the price of LEVOXYL 137 MCG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOXYL 137 MCG TABLET has risen 129.9%. It has been tracked across 611 weekly CMS publications since Apr 23, 2014.
What are the highest and lowest recorded NADAC prices for LEVOXYL 137 MCG TABLET?
Since Apr 23, 2014, the NADAC for LEVOXYL 137 MCG TABLET has ranged from a low of $0.5003 (Apr 23, 2014) to a high of $1.1520 (Jun 10, 2026), with a median of $1.0297 per EA.
Are there cheaper alternatives to LEVOXYL 137 MCG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVOTHYROXINE 137 MCG TABLET, is $0.0639 per EA — about 94% below LEVOXYL 137 MCG TABLET.
Who manufactures LEVOXYL 137 MCG TABLET?
LEVOXYL 137 MCG TABLET (NDC 60793085701) is labeled by Pfizer Inc., and CMS classifies it as a brand product.